Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib –


– Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib –


– Median...

Related Keywords

Germany ,Australia ,United States ,United Kingdom ,China ,Switzerland ,Singapore ,Hong Kong ,Taiwan ,Canada ,Israel ,New Zealand ,Macau ,West German ,Matthewl Sherman ,Sebastian Bauer ,Deciphera Pharmaceuticals Inc ,Linkedin ,Deciphera Pharmaceuticals ,European Union ,German Cancer Center ,Exchange Commission ,Nasdaq ,Nature Medicine ,Medical Oncologist ,West German Cancer Center ,Chief Medical Officer ,Objective Response Rate ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,